Marinus (MRNS) has been a controversial stock for some time, as the company looked to challenge Sage’s (SAGE) Zulresso with its “similar but different” compound ganaxolone, and questions about the efficacy of the drug and its chronic clinical timeline slips dogged the stock. Writing about the shares in late September of 2018, I very nearly top-ticked the stock and the shares declined sharply into the end of 2018 on growing doubts about both the post-partum and epilepsy pipelines before recovering into the mid-single-digits through April of this year.
With